Efficacy matters: broadening complement inhibition in COVID-19.
作者信息
Mastellos Dimitrios C, Skendros Panagiotis, Calado Rodrigo T, Risitano Antonio M, Lambris John D
机构信息
Division of Biodiagnostic Sciences and Technologies, INRASTES, National Center for Scientific Research "Demokritos", Athens, Greece.
First Department of Internal Medicine and Laboratory of Molecular Hematology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.
出版信息
Lancet Rheumatol. 2021 Feb;3(2):e95. doi: 10.1016/S2665-9913(20)30423-9. Epub 2020 Dec 14.
Abstract
摘要
相似文献
1
Efficacy matters: broadening complement inhibition in COVID-19.疗效至关重要：扩大对新冠病毒肺炎的补体抑制作用
Lancet Rheumatol. 2021 Feb;3(2):e95. doi: 10.1016/S2665-9913(20)30423-9. Epub 2020 Dec 14.
2
Efficacy matters: broadening complement inhibition in COVID-19 - Authors' reply.疗效很重要：扩大新冠病毒肺炎中的补体抑制作用——作者回复
Lancet Rheumatol. 2021 Feb;3(2):e95-e96. doi: 10.1016/S2665-9913(20)30424-0. Epub 2020 Dec 14.
3
Complement Activation in Kidneys of Patients With COVID-19.新型冠状病毒肺炎患者肾脏中的补体激活
Front Immunol. 2021 Jan 29;11:594849. doi: 10.3389/fimmu.2020.594849. eCollection 2020.
4
Decreased complement C3 levels are associated with poor prognosis in patients with COVID-19: A retrospective cohort study.补体 C3 水平降低与 COVID-19 患者的预后不良相关：一项回顾性队列研究。
Int Immunopharmacol. 2020 Dec;89(Pt A):107070. doi: 10.1016/j.intimp.2020.107070. Epub 2020 Oct 5.
5
Complement Inhibition in Coronavirus Disease (COVID)-19: A Neglected Therapeutic Option.冠状病毒病（COVID-19）中的补体抑制：一种被忽视的治疗选择。
Front Immunol. 2020 Jul 7;11:1661. doi: 10.3389/fimmu.2020.01661. eCollection 2020.
6
Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal Antibodies Targeting C5 Complement for Hematologic Disorders.3例接受靶向C5补体的治疗性单克隆抗体治疗血液系统疾病的COVID-19患者的临床病程较轻。
Am J Case Rep. 2020 Sep 12;21:e927418. doi: 10.12659/AJCR.927418.
7
Will Complement Inhibition Be the New Target in Treating COVID-19-Related Systemic Thrombosis?补体抑制会成为治疗新冠病毒相关全身性血栓形成的新靶点吗？
Circulation. 2020 Jun 2;141(22):1739-1741. doi: 10.1161/CIRCULATIONAHA.120.047419. Epub 2020 Apr 9.
8
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101.首例 COVID-19 患者接受补体 C3 抑制剂 AMY-101 治疗。
Clin Immunol. 2020 Jun;215:108450. doi: 10.1016/j.clim.2020.108450. Epub 2020 Apr 29.
9
Electron momentum densities near Dirac cones: Anisotropic Umklapp scattering and momentum broadening.狄拉克锥附近的电子动量密度：各向异性倒格矢散射与动量展宽
Sci Rep. 2017 Apr 3;7(1):565. doi: 10.1038/s41598-017-00628-4.
10
Managing COVID-19 outbreak in Nigeria: matters arising.尼日利亚应对 COVID-19 疫情：出现的问题。
Clin Chem Lab Med. 2020 Sep 25;58(10):1645-1650. doi: 10.1515/cclm-2020-0748.
引用本文的文献
1
Editorial: The impact of COVID-19 on immune system-related complications in surgical patients.社论：2019冠状病毒病对外科手术患者免疫系统相关并发症的影响
Front Surg. 2023 Jan 30;10:1132752. doi: 10.3389/fsurg.2023.1132752. eCollection 2023.
2
Genetic prediction of ICU hospitalization and mortality in COVID-19 patients using artificial neural networks.利用人工神经网络对 COVID-19 患者进行 ICU 住院和死亡的遗传预测。
J Cell Mol Med. 2022 Mar;26(5):1445-1455. doi: 10.1111/jcmm.17098. Epub 2022 Jan 22.
3
The Dual Role of a Polyvalent IgM/IgA-Enriched Immunoglobulin Preparation in Activating and Inhibiting the Complement System.富含多价IgM/IgA的免疫球蛋白制剂在激活和抑制补体系统中的双重作用
Biomedicines. 2021 Jul 14;9(7):817. doi: 10.3390/biomedicines9070817.
4
The COVIDome Explorer researcher portal.COVIDome Explorer 研究人员门户。
Cell Rep. 2021 Aug 17;36(7):109527. doi: 10.1016/j.celrep.2021.109527. Epub 2021 Jul 28.
5
The COVIDome Explorer Researcher Portal.新冠病毒基因组探索者研究人员门户。
medRxiv. 2021 Mar 8:2021.03.04.21252945. doi: 10.1101/2021.03.04.21252945.
6
Seroconversion stages COVID19 into distinct pathophysiological states.血清转化将 COVID19 分为不同的病理生理状态。
Elife. 2021 Mar 16;10:e65508. doi: 10.7554/eLife.65508.
本文引用的文献
1
Complement C5 inhibition in patients with COVID-19 - a promising target?新冠病毒肺炎患者中补体C5抑制——一个有前景的靶点？
Haematologica. 2020 Dec 1;105(12):2847-2850. doi: 10.3324/haematol.2020.260117.
2
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial.抗C5a抗体IFX-1（vilobelimab）治疗与最佳支持治疗对重症COVID-19患者的疗效比较（PANAMO）：一项探索性、开放标签的2期随机对照试验。
Lancet Rheumatol. 2020 Dec;2(12):e764-e773. doi: 10.1016/S2665-9913(20)30341-6. Epub 2020 Sep 28.
3
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.补体 C3 与 C5 抑制在重症 COVID-19 中的作用：早期临床发现揭示了不同的生物学疗效。
Clin Immunol. 2020 Nov;220:108598. doi: 10.1016/j.clim.2020.108598. Epub 2020 Sep 19.
4
Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis.补体和组织因子富集的中性粒细胞细胞外陷阱是 COVID-19 免疫血栓形成的关键驱动因素。
J Clin Invest. 2020 Nov 2;130(11):6151-6157. doi: 10.1172/JCI141374.
5
Complement as a target in COVID-19?补体作为 COVID-19 的靶点？
Nat Rev Immunol. 2020 Jun;20(6):343-344. doi: 10.1038/s41577-020-0320-7. Epub 2020 Apr 23.
Zotero 插件